Orexo AB - ESG Rating & Company Profile powered by AI
Other companies in the rating industry group for Orexo AB are displayedin the table. This assessment of Orexo AB uses intelligence from across the web and also from public filings by Orexo AB. The webpage displays a free Sustainability analysis for Orexo AB.
Orexo AB in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 8.0; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.
8.0
High ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Orexo AB | 8.0 | High |
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Orexo AB have an accelerator or VC vehicle to help deliver innovation?
Does Orexo AB disclose current and historical energy intensity?
Does Orexo AB report the average age of the workforce?
Does Orexo AB reference operational or capital allocation in relation to climate change?
Does Orexo AB disclose its ethnicity pay gap?
Does Orexo AB disclose cybersecurity risks?
Does Orexo AB offer flexible work?
Does Orexo AB have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Orexo AB disclose the number of employees in R&D functions?
Does Orexo AB conduct supply chain audits?
Does Orexo AB disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Orexo AB conduct 360 degree staff reviews?
Does Orexo AB disclose the individual responsible for D&I?
Does Orexo AB disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Orexo AB disclose current and / or historical scope 2 emissions?
Does Orexo AB disclose water use targets?
Does Orexo AB have careers partnerships with academic institutions?
Did Orexo AB have a product recall in the last two years?
Does Orexo AB disclose incidents of discrimination?
Does Orexo AB allow for Work Councils/Collective Agreements to be formed?
Has Orexo AB issued a profit warning in the past 24 months?
Does Orexo AB disclose parental leave metrics?
Does Orexo AB disclose climate scenario or pathway analysis?
Does Orexo AB disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Orexo AB disclose the pay ratio of women to men?
Does Orexo AB support suppliers with sustainability related research and development?
Does Orexo AB disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Orexo AB reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Orexo AB involved in embryonic stem cell research?
Does Orexo AB disclose GHG and Air Emissions intensity?
Does Orexo AB disclose its waste policy?
Does Orexo AB report according to TCFD requirements?
Does Orexo AB disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Orexo AB disclose energy use targets?
Does Orexo AB disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Orexo AB have a policy relating to cyber security?
Have a different question?
Potential Risks for Orexo AB
These potential risks are based on the size, segment and geographies of the company.
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.